Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 30,941 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $16.00, for a total value of $495,056.00. Following the transaction, the chief operating officer directly owned 575,235 shares in the company, valued at approximately $9,203,760. This trade represents a 5.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Julie Rubinstein also recently made the following trade(s):

• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total value of $484,845.47.

Adaptive Biotechnologies Price Performance

Shares of ADPT stock traded down $0.95 during trading hours on Friday, hitting $14.98. The stock had a trading volume of 587,082 shares, compared to its average volume of 1,855,177. The firm has a market capitalization of $2.31 billion, a PE ratio of -37.45 and a beta of 2.19. The stock’s 50 day moving average is $16.83 and its 200 day moving average is $15.79. Adaptive Biotechnologies Corporation has a twelve month low of $6.26 and a twelve month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company’s quarterly revenue was up 51.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.23) EPS. As a group, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ADPT shares. Guggenheim raised their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. JPMorgan Chase & Co. lifted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Morgan Stanley began coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target for the company. Finally, Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $18.25.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of large investors have recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Adaptive Biotechnologies in the 4th quarter valued at approximately $28,000. T. Rowe Price Investment Management Inc. purchased a new position in Adaptive Biotechnologies in the fourth quarter worth $51,000. Invesco Ltd. lifted its holdings in Adaptive Biotechnologies by 248.8% in the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after acquiring an additional 2,216,595 shares during the period. Corient Private Wealth LLC boosted its position in shares of Adaptive Biotechnologies by 3.4% during the 4th quarter. Corient Private Wealth LLC now owns 71,908 shares of the company’s stock worth $1,168,000 after purchasing an additional 2,347 shares in the last quarter. Finally, Strive Financial Group LLC acquired a new position in shares of Adaptive Biotechnologies during the 4th quarter worth $52,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.